has reached 83% in patients supported with newer-generation continuous-flow VADs. 12 Although follow-up remains too short to draw conclusions about long-term outcomes, advances in VAD technology hold significant promise.
VAD therapy is most frequently used as a bridge to transplantation (BTT-VAD). Approximately 85% of patients who receive a device are listed on the transplantation waiting list at the time of VAD implantation or during support. 13 VAD therapy is associated with frequent complications, including but not limited to renal failure, infection, sensitization, and thromboembolism, which may increase the risk of posttransplantation adverse events. [14] [15] [16] [17] The benefits and risks associated with HTx and VAD therapy in addition to the lack of comparative studies on these therapies make it difficult to confidently determine which approach is best on the basis of individual patient characteristics. In this setting, decision analytic models may be useful to assist clinical decision making. Therefore, the objective of the present study was to perform a decision analysis to evaluate the clinical benefits and costs associated with BTT-VAD Figure 1 . Markov model for heart transplantation (HTx) and ventricular assist device (VAD) as a bridge to transplantation as treatment strategies for heart transplantation candidates. Simulated VAD cohort starts the model in the bridgeto-transplantation state, and simulated cohort of nonbridged HTx recipients initiates the model in the heart failure waiting list state. A, Base model. B, Model including post-HTx and post-VAD complications. CAV indicates cardiac allograft vasculopathy; CRD, chronic renal dysfunction; and HF, heart failure.
Table 1. Description of INTERMACS Levels and UNOS Status
Status Model Categories Description
INTERMACS Level

UNOS Status
High risk Persistent hypotension despite rapidly escalating inotropic support and eventually IABP, and critical organ hypoperfusion 1 1A
Intravenous inotropic support with acceptable values of blood pressure and continuing deterioration in nutrition, renal function, or fluid retention 2 Medium risk Stability reached with mild to moderate doses of inotropes but demonstrating failure to wean from them because of hypotension, worsening symptoms, or progressive renal dysfunction 3 1B
Low risk Possible weaning of inotropes but experiencing recurrent relapses, usually fluid retention 4 2 Severely limited tolerance for activity: comfortable at rest with some volume overload and often with some renal dysfunction 5
Less severely limited tolerance for activity and lack of volume overload; fatigues easily 6
Methods
To assess the clinical benefits and economic impact of nonbridged HTx and BTT-VAD therapy as treatment strategies for patients with advanced HF, we constructed an economic model based on outcome probabilities from published studies and costs from a cohort of patients with advanced HF seen at the Toronto General Hospital using Microsoft Excel 2007. The model estimated the outcomes for patients undergoing 2 treatment strategies: nonbridged HTx and implantation of a BTT-VAD with subsequent HTx. Model outputs were represented in terms of life years (LYs), cost, and cost-effectiveness ratio (CER).
Model Description
The decision analytic Markov model ( Figure 1 ) was used to project the outcomes and costs of the 2 treatment pathways (nonbridged HTx cohort and BTT-VAD cohort). The HTx cohort started from the HF waiting state (ie, being on a waiting list for HTx) and could progress to HTx, BTT-VAD, or death. The BTT-VAD cohort started from the BTT-VAD state and could progress to HTx or death. After receiving HTx or a VAD, patients could develop complications. We defined post-HTx and post-VAD complications according to the criteria used by the probability data source (see definitions in Table I in the onlineonly Data Supplement). The patient population consisted of a cohort of patients with advanced HF failure who were transplantation candidates. As shown in Table 1 , we derived 3 scenarios by categorizing patients according to their baseline hemodynamic status using United Network for Organ Sharing (UNOS) status 18 or INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profiles 19 : High risk, which included transition probabilities for patients with UNOS status 1A and INTERMCAS 1 and 2 profiles; medium risk, which included transition probabilities for UNOS status 1B and INTERMACS 3 profiles; and low risk, which included transition probabilities for patients with UNOS status 2 and INTERMACS 4 to 7 profiles. Common characteristics of the 3 base case scenarios were age 55 years and the presence of normal renal function. The analytic time horizon was set at a life span of 75 years, representing 20 years of the analytic time.
The assumptions of the model, made in concordance with expert opinion, were as follows: (1) A patient in a given state could make only a single state transition during a cycle; (2) transitions were considered to occur at the midpoint of each cycle; (3) all patients were transplantation candidates; (4) a patient could undergo a VAD implantation and subsequent transplantation but not vice versa; (5) the pre-VAD mortality in patients undergoing VAD implantation was considered null; (6) a second VAD or transplantation was not considered an option in this model; (7) patients transitioning from the HF waiting state to the BTT-VAD state were considered to be hemodynamically worse than at the beginning of the model; (9) patients transitioning from the BTT-VAD state to the HTx state were considered to be hemodynamically better than the initial profile; (10) the probability of death may be increased after the development of post-HTx or post-VAD complications, and therefore, patients could not return to the BTT-VAD or HTx state after developing any complication; (11) the development of any post-VAD or posttransplantation complication was assumed to be exclusive, which meant that patients could not develop 2 complications simultaneously; (12) the probabilities of posttransplantation outcomes were deemed to be similar in patients coming from different states (ie, HF waiting or BTT-VAD states), based on evidence from previous studies 17, 20, 21 ; and (13) available outcome data in patients undergoing VAD implantation were based on 3-and 10-year follow-up in the case of transplantation outcomes, constant probabilities were used to calculate outcomes in subsequent years.
Outcome Probability Data
Because of the lack of randomized, controlled trials or observational studies comparing these 2 strategies incorporating the waiting Eligible articles that reported studies that had enrolled adults (>19 years) who were heart transplantation candidates and that reported on wait-list mortality, post-VAD outcomes, or posttransplantation outcomes were included in the present analysis. There were no restrictions on study design, but we included only articles in English. In the case of multiple studies reporting on the same outcomes, we selected the most recent.
Data were derived mainly from registry data, including the UNOS database, 10, 18, 22, 23 the International Society of Heart and Lung Transplantation registry, 24 INTERMACS, 13, 25, 26 and the United Kingdom national database. 27 When the INTERMACS registry did not report the required data, results from studies on HeartMate II patients were used. 28 Table II in the online-only Data Supplement summarizes the characteristic of studies selected.
In general, the baseline transition probabilities were obtained from survival curves. The probabilities applied during the first year were considered to be time dependent and were calculated for each 3-month interval. After the first year, we calculated the transition probabilities based on 1-year time intervals assuming that they had an exponential distribution and were constant over time. When dispersion measurement was not reported, we calculated 95% confidence intervals. Tables 2 and 3 summarizes the probabilities and their respective 95% confidence intervals.
Cost Data
Cost information was obtained from a cohort of advanced HF patients undergoing HTx (120 patients) or continuous-flow VAD implantation (34 patients: 23 HeartMate II, 9 HeartWare, and 2 DuraHeart devices) between 2006 and 2011 at the Toronto General Hospital (tertiary care hospital). The costs collected included inpatient and outpatient costs. Inpatient costs were derived from the following: (1) operating room overhead, including nursing staff, surgical supplies, and infrastructure costs; (2) intensive care unit and ward room costs for the index admission and preintervention and postintervention hospital admissions; (3) drugs and pharmacy labor costs; (4) diagnostic tests (radiographs, ultrasounds, blood tests, microbiology, and pathology tests); and (5) the device cost in patients undergoing a VAD implantation. Outpatients costs included (1) follow-up visits with the surgeon, cardiologist, and other specialists (eg, consultation with a hematologist or infectious disease physician); (2) visits to emergency room; (3) diagnostic tests required; and (4) drugs and pharmacy labor costs.
On the basis of the collected information, we calculated mean costs and SDs for 3-month intervals during the first year and annually thereafter. Costs were assumed to be the same in patients with and without posttransplantation or post-VAD complications. Costs from various years were inflated to and expressed in 2011 Canadian dollars using the consumer price index from Statistics Canada (www.statcan. gc.ca). We applied an annual discount of 5%.
Sensitivity Analysis
We performed deterministic and probabilistic sensitivity analyses on probability and cost data estimated at a 75-year life span (20 years of the analytic time) for the 3 possible base cases. We performed a range of 1-way deterministic sensitivity analyses by varying all the probabilities, one at a time, outlined in Table 2 using the upper and lower bounds of their respective 95% confidence intervals and the cost data using the values of quartiles 1 and 3. We represented the results from these analyses using a Tornado diagram plotting only estimates for which the CER changed >5% from the value of the base case.
We also conducted a probabilistic sensitivity analysis by simultaneously and randomly varying the probabilities and cost data using a β-distribution for probability data and a γ-distribution for cost data. By running the model 1000 times using a Monte Carlo simulation, we reproduced 1000 pairs of the effectiveness (LYs) and costs associated with BTT-VAD therapy relative to nonbridged HTx. These results were then plotted on a cost-effectiveness plane and used to produce a cost-effectiveness acceptability curve that illustrated the probability that BTT-VAD therapy was cost-effective compared with nonbridged HTx for a range of willingness-to-pay (WTP) values per LY gained.
In the cost-effectiveness acceptability curve, a probability >50% means that BTT-VAD has a higher probability of being cost-effective than HTx at a given WTP. The cost-effectiveness acceptability curve shows the proportion of the simulated results that lie below a given decision-making threshold, which is varied over a wide range of thresholds, to derive the acceptability curve.
Subgroup Analysis
We populated different scenarios addressing the development of posttransplantation complications (chronic renal dysfunction, coronary allograft vasculopathy, rejection, and cancer) and VAD complications (infection). We analyzed only complications that changed posttransplantation and post-VAD mortality. On the basis of available reports, bleeding and strokes during VAD support are not associated with increased mortality. 25, 28 We also modeled different scenarios based on changes in the probability of transplantation (transition probability from HF waiting state to HTx state) according to blood group type, as well as a scenario that considered a range of different ages (<45, 60, and >70 years) and the presence of renal dysfunction (creatinine >1.5 mg/dL). Table IV in the online-only Data Supplement cites the relative risks associated with changes in the characteristic of the base case.
These analyses were performed with a probabilistic sensitivity analysis. Results are presented using multiple acceptability curves.
Results
Clinical Outcomes
The estimated survival in the simulated cohort of high-and medium-risk patients was higher in patients undergoing BTT-VAD implantation than in HF patients waiting for transplantation throughout the analytic time (Figure 2A ). In the simulated cohort of low-risk HF patients, survival during the first years of the analytic time was reduced compared with nonbridged HTx patients; however, after this initial time, survival in patients undergoing VAD implantation was slightly increased. The simulated median survival time in high-risk nonbridged HTx recipients was 11 years versus 15 years in BTT-VAD patients; in medium-risk patients, the simulated median survival was 13 and 16.5 years, respectively; and in low-risk patients, the simulated median survival was 17 and 20 years, respectively.
Cost Outcomes
Baseline characteristics of patients from whom the cost data were obtained are described in Table V in the online-only Data Supplement. The mean age of heart transplant recipients was 48±13 years, and 73 patients (61%) were male. Fifty-seven patients (47%) were UNOS status 2 at the time of transplantation, and 33 (28%) and 30 (25%) were UNOS status 1A and 1B, respectively. The mean age of patients undergoing VAD implantation was 50.6±12 years, and 20 (59%) were male. Most patients (94%) were INTERMACS profile 3 or better at the time of VAD implantation. The cumulative discounted costs estimated by the model were higher in patients undergoing VAD implantation at any given time point during the analytic period. Estimated imputed individual patient costs at different time points are shown in Table 4 . As shown in Figure 2B , the main difference in costs was related to the early post-VAD and posttransplantation period. Table VI in the online-only Data Supplement summarizes the average in-hospital cost per patient of resources used during the first 3 months. The estimated 1-year cost in high-, medium-, and low-risk patients was $226 400, $230 300 and $232 300 Canadian dollars, respectively, in patients undergoing VAD implantation and $93 900, $87 300, and $60 100 Canadian dollars, respectively, in the nonbridged HTx cohort. In general, after this initial period, the discounted estimated costs showed a slightly gradual increase with both strategies ( Figure 2B ).
Cost-Effectiveness Analysis
The results from the present analysis projected improvements in clinical outcomes with increased costs in HF patients undergoing a BTT-VAD implantation versus nonbridged HTx patients. Table 5 shows the estimated values of the cost-effectiveness analysis at different time points; CER was higher at time points that represented shorter analytic times. At a time horizon of 20 years (representing a life span of 75 years), BTT-VAD therapy increased survival at increased cost relative to nonbridged heart transplant recipients: $100 841 more and 1.19 increased LYs in high-risk patients ($84 964/ LY), $112 779 more and 1.14 more LYs ($99 039/LY) in medium-risk patients, and an additional cost of $144 334 and incremental clinical benefit of 1.21 more LYs ($119 574/LY) in low-risk patients.
Sensitivity Analysis
The results of the deterministic sensitivity analysis are presented in Figure I in the online-only Data Supplement. The main factors that affected the CER were the uncertainty surrounding mortality during VAD support and costs. The CER estimated in the probabilistic sensitivity analysis at 20 years are very similar to those estimated in the deterministic analysis. These are presented in Figure 3 . When these results were used to generate a cost-effectiveness acceptability curve, there was a 59%, 54%, and 43% likelihood of BTT-VAD therapy being regarded as cost-effective versus nonbridged HTx patients among high-, medium-, and low-risk patients, respectively, at a WTP threshold of $100 000/LY (Figure 4) .
Subgroup Analysis
The probability of BTT-VAD therapy being cost-effective at a WTP of $100 000/LY was increased in patients with any posttransplantation complications, ≈85% to 90% among patients developing rejection and ≈70% when the rest of the posttransplantation complications were analyzed. The development of VAD-related infections significantly reduced the probability of VAD being cost-effective in all cases ( Figure 5 ).
The probability of BTT-VAD therapy being cost-effective at a WTP of $100 000/LY was reduced in high-risk patients when the expected waiting time was shorter, such as in blood group B and AB patients, and increased when expected time was longer (blood groups A and O). The probability of BTT-VAD therapy being cost-effective remained relatively unchanged in medium-and low-risk patients in any of the different simulated scenarios according to blood type ( Figure 6 ).
Subgroup analysis according to different ages showed that the probability of BTT-VAD therapy being cost-effective at a WTP of $100 000/LY was slightly increased in 45-year-old patients and decreased to <35% in patients >70 years of age ( Figure 7 ). Subgroup analysis according to the presence of renal dysfunction demonstrated that the probability of VAD therapy being cost-effective increased, at a WTP of $100 000/ LY, ≈70% and 60% in high-and medium-risk patients, respectively ( Figure 8) .
Discussion
This modeling analysis suggests that BTT-VAD therapy in patients with advanced HF may represent a cost-effective treatment option generating additional clinical benefit at an increased cost, especially in high-and medium-risk patients. At the 20-year time horizon, BTT-VAD therapy had an added cost $84 964/LY and $99 039/LY compared with nonbridged HTx recipients among high-and medium-risk patients, respectively. Among low-risk patients, VAD therapy was associated with impaired clinical outcomes during the early analytic period; however, at the 20-year time horizon, BTT-VAD was associated with clinical benefits and increased costs and incurred an additional cost of $110 324/LY compared with nonbridged HTx patients.
In Canada, based on a review of previous economic evaluations performed in 1992, 3 arbitrary cutoffs have been proposed to grade recommendations of cost-effective therapies. 29 On the basis of these cutoffs, we would conclude that a WTP of $100 000 for BTT-VAD therapy as a treatment option for advanced HF patients would represent a cost-effective strategy On the basis of the results of the sensitivity and subgroup analyses, some of the main factors impacting the cost per LY gained in high-and medium-risk BTT-VAD patients versus nonbridged HTx patients are mortality during VAD support, the development of posttransplantation rejection, VADrelated infection, and costs associated with these therapies. The study by Starling et al 25 analyzing outcomes in contemporary HeartMate II patients showed that 1-year survival in VAD patients was substantially improved, from 68% in the first trial of BTT-HeartMate II patients 30 to 87% in the current era (absolute risk reduction of 19%). Importantly, they also reported a significant decrease in the rate of infections per patient (VAD-and non-VAD-related infections). On the basis of these improved outcomes, future survival estimates may be expected to be incrementally better although smaller in magnitude, promising a reduced CER.
Similarly, a lower risk of posttransplantation complications also improved the CER of BTT-VAD therapy. Although it is difficult to accurately estimate the risk of posttransplantation complications during HTx assessment, candidates who are highly sensitized and potentially at high risk for posttransplantation rejection may benefit from BTT-VAD therapy by delaying the exposure to the increased posttransplantation mortality associated with rejection. 20 The CER of BTT-VAD therapy versus nonbridged HTx recipients may also be modified by the waiting time. In this Figure 4 . Probability of therapy with ventricular assist device as bridge to transplantation (VAD) being cost-effective relative to heart transplantation (HTx) according to willingness to pay based on baseline hemodynamic profile (high, medium, and low risk). Cost-effectiveness ratios represent the cost associated with 1 life year gained. CER indicates cost-effectiveness ratio (cost per life year); HTx, heart transplant; and VAD, ventricular assist device.
*Costs are expressed in 2011 Canadian dollars.
by guest on April 21, 2017 http://circ.ahajournals.org/ Downloaded from context, for blood group B and AB patients, the median waiting time is ≈2.5 months (95% confidence interval, 2-5 months). 27 This short waiting time implies a lower mortality while awaiting HTx for these groups of patients. In blood groups A or O, primarily in high-risk patients, BTT-VAD represents a more cost-effective therapy, but in blood group AB or B patients, nonbridged HTx was the most cost-effective therapy.
In patients who had moderate to severe renal dysfunction (creatinine >1.5 mg/dL), BTT-VAD therapy was highly likely to be considered cost-effective. Renal dysfunction has been identified as an important risk factor for mortality in patients with advanced HF, 10 as well as being a predictor of early and longterm posttransplantation mortality. 24 Conversely, renal dysfunction does not represent a factor associated with mortality during VAD support. 12, 13 In fact, renal function improves during VAD support because of improvements in hemodynamic profile and organ perfusion. 31 This scenario makes BTT-VAD therapy an efficacious therapeutic option for patients with renal dysfunction, which constitutes one of the main indications for VAD therapy as a bridge to HTx candidacy. 12 In patients with low-risk status, BTT-VAD therapy was associated with decreased survival and increased cost in the first 5 years of the analytic period. Afterward, the effectiveness of BTT-VAD therapy increased. However, the deterministic sensitivity analysis identified many situations in which BTT-VAD therapy may be associated with decreased survival or considerably higher costs, which makes this strategy even less appealing. The increased CER associated with BTT-VAD Figure 5 . Probability of therapy with ventricular assist device as bridge to transplantation (VAD) being cost-effective relative to heart transplantation (HTx) according to willingness to pay based on the development of posttransplantation and post-VAD complications in high-(A), medium-(B), and low-risk (C) patients with heart failure. CAV indicates cardiac allograft vasculopathy; and CRD, chronic renal dysfunction. therapy in low-risk patients is clearly perceived within the expert community, because patients with INTERMACS 5 to 7 profiles represent a small proportion (≈6%) of the overall VADs implanted between 2009 and 2010. 12, 13 There is a paucity of economic evidence for the use of BTT-VAD therapy. A previous economic evaluation of VAD therapy compared with standard medical care in HF patients conducted in the United Kingdom reported that at a 5-year time horizon, VAD therapy was associated with an improved survival of 18 months and increased costs of £99 475 (CER of £65 242/QALY). 32 The probability of VAD therapy being costeffective was null for a regionally commonly accepted WTP of £30 000/QALY. Similar results were reported in a more recent economic evaluation. 33 These reports showed a higher CER than in the present study; however, the models, outcomes, treatment strategies analyzed, and time horizon are not comparable between the studies, mainly because these reports did not include analysis of posttransplantation outcomes. 
Study Limitations
Although the present model appears to produce clinically realistic projections, there are some limitations that should be noted. First, this is a model and does not represent empirically collected clinical outcomes. However, in the absence of comparative clinical data on VAD therapy and HTx that include mortality while patients are on the waiting list, a computer simulation represents the best alternative solution. The model was constructed from data from large published registries, and a number of assumptions, clearly detailed, were made, which allows readers to easily assess its validity.
A potential additional limitation of the present analysis is that we did not incorporate quality of life as a clinical outcome. We believe that there are no compelling data suggesting that quality of life may be different in VAD versus HTx patients. 17, 34 Although quality of life is clearly impaired in patients with advanced HF, we opted not to include this to avoid bias related to its subjective measurement.
Another important concern when building this model was related to the generalizability of the model outcomes. We believe that patients included in the data sources represent a typical cohort of HF patients treated in advanced care centers. As has been suggested, 35 results from large observational long-term studies from registry data are more generalizable (increased external validity) than results from randomized, controlled trials, which usually include less sick patients and address relatively short-term outcomes.
When considering results from a computer simulation model, it is ideal to validate the clinical outcomes against empirical data. In this regard, our model projects similar post-VAD survival estimates to those reported by the UNOS database and INTERMACS. 10, 13, 18 There are no empirical data to compare model-estimated posttransplantation survival, which includes survival during waiting time.
Because of the lack of reports on short-and long-term costs of VAD therapy, we used cost data from a single institution derived from a small group of patients; this may lead to bias, and results may not be entirely generalizable. However, cost estimates are similar to those reported by Slaughter et al. 36 They analyzed in-hospital costs in 83 patients who had a continuous-flow VAD and presented a similar mean cost of US $193 812 during index hospital admission (mean hospital stay, 27 days; SD, 17 days) versus our estimated cost of $212 232 during the first 3 months of VAD support.
Data from individual centers may not completely match the clinical data and costs imputed in the present model. Centers should evaluate potential differences and be cautious when extrapolating these results to their practice.
Conclusions
This economic evaluation showed that BTT-VAD therapy offers improved survival at increased costs. The present study suggests that BTT-VAD therapy represents a cost-effective strategy in patients with advanced HF in some circumstances, including high-and medium-risk patients with expected long waiting times for transplantation, patients with renal dysfunction, those with a high risk of posttransplantation complications, and young patients. Some scenarios explored in the present analysis may help healthcare providers perform informed decision making to improve outcomes and reduce costs associated with the management of patients with advanced HF. Rejection [1] Defined by the presence of at least one acute rejection episode that was treated with anti-rejection therapy o was hospitalized for rejection. There was no distinction between cellular and antibody-mediated rejection.
Chronic renal
dysfunction [1] Defined by the presence of creatinine >2.5 mg/dl (221 μmol/L), dialysis or renal transplant during the post-transplant period.
Cardiac allograft
vasculopathy [1] Defined by the presence of any degree of angiographic evidence of coronary artery disease.
Cancer [1] Defined by the presence of any type of malignancy including skim cancer, lymphoproliferative malignancies and other types, including prostate, adenocarcinoma, lung, bladder, renal, breast and colon cancer, and Kaposi sarcoma.
Infections [2] Defined by the presence of VAD related and non-VAD related infections as a clinical infection that is treated by anti-microbial agents (non-prophylactic). A positive culture from the infected site or organ should be present unless strong clinical evidence indicates the need for treatment despite negative cultures.
Stroke [3] Defined by the presence of any new focal or global neurological deficit ascertained by a standard neurological examination (administered by a neurologist or other qualified physician) which lasts longer than 24 hours (or less than 24 hours if there is evidence of infarction). The event may be ischemic or hemorrhagic.
Bleeding [4] Defined by the presence of one or more of the following symptoms: guaiac-positive stool; hematemesis; melena; active bleeding at the time of endoscopy or colonoscopy;
and blood within the stomach at endoscopy or colonoscopy. 
